Update on R&D Pipeline

SPARC Provides Update on Pivotal Phase III Studies of Baclofen GRS for Treatment of Spasticity in Patients with Multiple Sclerosis

SPARC Announces Top-line Results of Pivotal Peak Inspiratory Flow (PIF) study and Low Dose Pharmacokinetic (PK) Study for Salmeterol – Fluticasone Dry Powder Inhaler (SPARC DPI)

Announcement - Receipt of reclassification approval from BSE

Announcement - Receipt of reclassification approval from NSE

Update on NCE and NDDS Programs

SPARC Licenses ELEPSIATM XR (Levetiracetam ER Tablets) to Sun Pharma

Update on XELP ROST and Elepsia XRT

SPARC Receives Complete Response Letter (CRL) from USFDA for Levetiracetam NDA

SPARC Receives Complete Response Letter (CRL) from USFDA for Latanoprost NDA